GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Interest Coverage

SLXN (Silexion Therapeutics) Interest Coverage : 0 (At Loss) (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Silexion Therapeutics's Operating Income for the three months ended in Sep. 2024 was $-8.04 Mil. Silexion Therapeutics's Interest Expense for the three months ended in Sep. 2024 was $-4.84 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Silexion Therapeutics's Interest Coverage or its related term are showing as below:


SLXN's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 137.08
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Silexion Therapeutics Interest Coverage Historical Data

The historical data trend for Silexion Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Silexion Therapeutics Interest Coverage Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23
Interest Coverage
- -

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Coverage Get a 7-Day Free Trial - N/A N/A - -

Competitive Comparison of Silexion Therapeutics's Interest Coverage

For the Biotechnology subindustry, Silexion Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silexion Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Silexion Therapeutics's Interest Coverage falls into.


Silexion Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Silexion Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Silexion Therapeutics's Interest Expense was $-0.01 Mil. Its Operating Income was $-4.68 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.06 Mil.

Silexion Therapeutics did not have earnings to cover the interest expense.

Silexion Therapeutics's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Here, for the three months ended in Sep. 2024, Silexion Therapeutics's Interest Expense was $-4.84 Mil. Its Operating Income was $-8.04 Mil. And its Long-Term Debt & Capital Lease Obligation was $4.08 Mil.

Silexion Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Silexion Therapeutics  (NAS:SLXN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Silexion Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Interest Coverage
Comparable Companies
Traded in Other Exchanges
N/A
Address
2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871
Website
https://www.silexion.com
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.